Spelling suggestions: "subject:"4he pharmaceutical aindustry"" "subject:"4he pharmaceutical anindustry""
81 |
The discursive function and the embedding of capitalism : British state policy on the pharmaceuticals and biotechnology sectorLarsen, David Mark January 2010 (has links)
No description available.
|
82 |
An evaluation of the roles and responsibilities of a product manager in the pharmaceutical industry.Naidoo, Selena. January 2003 (has links)
Product managers typically have job descriptions listing their duties and responsibilities. These itemized lists identify the requirements of the job and are used to measure the product managers' success. They provide the what of the job, but they don't always include the how. ( Gorchels, 2003, p1) The objectives of the research was: - To determine best practices for product managers to perform their roles in the pharmaceutical industry - To evaluate current beliefs and practices of product managers regarding their roles and responsibilities in the pharmaceutical industry. - To establish ways to improve poor practices and provide guidance to product managers in the pharmaceutical industry. The study was conducted amongst product managers in a leading pharmaceutical company. The findings indicated that there some problems were experienced in the company .It was also evident that while there were some good practices in the division, poor methods of practice were also being conducted by the product managers. Implementing the recommendations proposed may enable the product managers to successfully perform their relevant roles and effectively execute their responsibilities within the pharmaceutical industry. / Thesis (MBA)-University of Natal, 2003.
|
83 |
Open ownership of pharmacies reduces the quality of pharmaceutical care for the consumer.Naicker, Kevin January 2003 (has links)
South Africa is currently grappling with amendments to a number of laws relating to the
supply of drugs. One of these amendments removes the requirement that only a pharmacist
may own an interest in a retail pharmacy. While this may be opposed by retail pharmacists,
the question is really: Will this measure benefit consumers by improving the access to drugs
by bringing to this sector a measure of competition and hence reduced prices or will this
measure reduce the quality of pharmaceutical care for consumers due to a lack of a
relationship based on trust? The emergence of brands such as HealthPharm (Pick 'n Pay),
Purchase Milton & Associates- PM&A (New Clicks), and the Checkers (Shoprite Group of
Companies) are becoming increasingly popular among consumers (Andy Gray, 1997). This
study investigates the impact of these changes on the consumer receiving affordable quality
pharmaceutical care. It aims to establish a relationship between consumers and their
pharmacist that is based on trust. Quantitative analysis of consumers and pharmacists revealed
that there is a relationship based on trust between these parties. Statistical analysis of these
samples also reveal a consumer trend suggesting that consumers and pharmacists require a
relationship based on trust to achieve the goals of pharmaceutical care. Open ownership of
pharmacies will not provide the consumer with an opportunity to develop this relationship
with their pharmacist and thus reduce the quality of pharmaceutical care received. / Thesis (MBA)-University of Natal, Durban, 2003.
|
84 |
Deadly gaps in the patent system : an analysis of current and alternative mechanisms for incentivising development of medical therapies.Kerdemelidis, Savvas January 2014 (has links)
The cost of medicines imposes a significant financial burden on society, with New Zealand spending $783.6 million between 2012 and 2013 alone. The majority of these costs are due to the monopoly prices charged for new patented drugs. The pharmaceutical industry argues that these high prices are necessary to recover the costs of drug development, which can exceed a billion dollars for a single drug. Because new medicines are relatively cheap to reverse-engineer and manufacture, in absence of a minimum period of exclusivity provided by patents, it is alleged that it would not be commercially viable to develop new medicines.
Most criticisms of the patent system relate to the high prices charged for patented medicines. However, there is another issue which has received limited academic commentary to date, namely, whether the pharmaceutical industry’s reliance on patents means that otherwise socially valuable medical therapies are being screened out or ignored, and whether alternative incentive mechanisms are needed to address this problem.
The aim of this thesis is to address this issue. First, the laws applicable to patentability and regulatory approval of new medicines will be discussed, with a focus on New Zealand and the United States. Second, evidence will be provided for the existence of three broad categories of medical therapies which lack private incentives for development under the current patent system: unpatentable therapies, unmonopolisable therapies and unprofitable therapies. Other problems with the reliance on patent monopolies will also be discussed. Third, the process of pharmaceutical reimbursement that is used to determine the price of medicines under the current system will be described, and a set of criteria will be proposed for an ideal incentive system, against which the current system is compared. Fourth, alternative incentive mechanisms for medical therapies comprising exclusivity-based ‘pull’ incentives, prize-based ‘pull’ incentives, and publicly funded ‘push’ incentives, will be analysed and ranked against these ideal criteria. This thesis concludes by proposing two legislative frameworks as part of an optimal incentive system alongside the current patent system, namely, extended regulatory exclusivity for incentivising unpatentable therapies and a prize-based mechanism combined with increased public funding for incentivising unmonopolisable and unprofitable therapies.
|
85 |
Foreign pharmaceutical firms' FDI entry strategies into China /Jiang, Fuming. January 2001 (has links)
Thesis (Ph.D.) -- Swinburne University of Technology, Graduate School of Entrepreneurship, 2000. / Submitted for the degree of Doctor of Philosophy, Australian Graduate School of Entrepreneurship, Swinburne University of Technology 2001. Typescript. Includes bibliographical references (p. 348-367).
|
86 |
Heroin importation and higher level drug dealing in Australia : opportunistic entrepreneurialism /Beyer, Lorraine R. January 2005 (has links)
Thesis (Ph.D.)--University of Melbourne, Dept. of Criminology, 2005. / Typescript. Includes bibliographical references (leaves: 221-238).
|
87 |
Three essays on marketing strategy elements and the brand life cycle in the pharmaceutical industryCavusgil, Erin. January 2008 (has links)
Thesis (Ph. D.)--Michigan State University. Dept. of Marketing, 2008. / Title from PDF t.p. (Mar. 26, 2009). Includes bibliographical references (p. 104-116). Also issued in print.
|
88 |
Bayesian approaches to problems in drug safety and adaptive clinical trial designsMauldin, Jo A. Seaman, John Weldon, January 2008 (has links)
Thesis (Ph.D.)--Baylor University, 2008. / Includes bibliographical references (p. 112-117).
|
89 |
Three essays in healthcare operations managementDeo, Sarang, January 2007 (has links)
Thesis (Ph. D.)--UCLA, 2007. / Vita. Includes bibliographical references (leaves 103-118).
|
90 |
The influence of the rural survivalist culture on corporate imageBotha, Frances-Marie. January 2006 (has links)
Thesis (Ph.D. (Organisational Behaviour)) -- University of Pretoria, 2006. / Abstract in English. Includes bibliographical references. Available on the Internet via the World Wide Web.
|
Page generated in 0.0791 seconds